A meaningful slice of reported profit is not turning into cash.
Valuation
15th pctvs its own history
Cheap
Its valuation sits in the cheaper end of its own recent range.
Revenue growth
-0.3%year over year
Weak
Revenue is contracting year over year.
Leverage
Lowdebt to assets
Healthy
A modest, well-covered debt load.
More coming: dilution / share-count creep.
Fair value
Undervalued
Trading about 5% below our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
ADMA Biologics Inc turns 78¢ of every reported profit-dollar into real cash. A meaningful slice of reported profit is not turning into cash. Revenue is contracting year over year. Its valuation sits in the cheaper end of its own recent range. A modest, well-covered debt load.
Key numbers
Valuation
EPS (TTM)$0.68
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin32.4%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$509.86M
TTM (trailing 12 months, through fiscal Q1 FY2026)
🔒 Watchlist alerts — get notified when a signal turnsPro
MONDAY INVESTOR DEADLINE: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - ADMA
DEADLINE ALERT for FUTU, FSLR, BRCB, ADMA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
DEADLINE NEXT WEEK: Hagens Berman Advises ADMA Biologics, Inc. Investors to Contact the Firm Before August 10, 2026
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline